<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04045392</url>
  </required_header>
  <id_info>
    <org_study_id>3-2019-0140</org_study_id>
    <nct_id>NCT04045392</nct_id>
  </id_info>
  <brief_title>Effects of Mediterranean Diet Based Intervention in Breast Cancer Patients</brief_title>
  <official_title>Effects of Mediterranean Diet Based Intervention in Postmenopausal Women With Breast Cancer Receiving Adjuvant Hormone Therapy: the Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gangnam Severance Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized clinical trial is to examine the effects of Mediterranean diet
      based intervention on inflammation and metabolic risk factors in overweight or obese
      postmenopausal women with breast cancer receiving adjuvant hormone therapy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2019</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in C-Reactive Protein (CRP) levels</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>Blood will be drawn from the participants for assessment of CRP levels (mg/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in fasting insulin levels</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>Blood will be drawn from the participants for assessment of fasting insulin levels (mcIU/mL) after fasting for at least 8 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in fasting glucose levels</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>Blood will be drawn from the participants for assessment of fasting glucose levels (mg/dL) after fasting for at least 8 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in lipid profile</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>Blood will be drawn from the participants for assessment of total cholesterol, triglyceride, HDL-cholesterol, and LDL-cholesterol (mg/dL) after fasting for at least 8 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>We will measure body weight (kg) of participants using the same scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fat mass measured by bioelectrical impedance analyzer</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>We will measure fat mass (kg) using bioelectrical impedance analyzer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life assessed by EORTC QLQ-C30 questionnaire</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>Quality of life will be assessed by questionnaire, named European Organisation for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30), score range 0~100, higher scores indicate better quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life assessed by OP scale questionnaire</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>Quality of life will be assessed by questionnaire, named Obesity-related problems scale (OP scale), scale range 0~100, higher scores indicate more problems</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Mediterranean diet group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mediterranean diet with calorie restriction below 1,500 kcal per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional diet group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Conventional diet with calorie restriction below 1,500 kcal per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Mediterranean diet</intervention_name>
    <description>Two meals (breakfast and dinner) a day, five times a week, are delivered to participants' homes without charge. The meals are prepared, under the supervision of an expert nutritionist, by a chef trained on the principles of the Mediterranean diet.</description>
    <arm_group_label>Mediterranean diet group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Breast cancer patients who are receiving adjuvant hormone therapy after diagnosed with
             breast cancer stage Ⅰ-Ⅲ and have completed cancer treatment including breast surgery
             and/or adjuvant chemotherapy, radiotherapy

          -  Postmenopausal women

          -  Body mass index (BMI) ≥23 kg/m2

          -  Able to speak and read Korean

          -  Able to comply with all required study procedures and schedule

          -  Willing and able to give written informed consent

        Exclusion Criteria:

          -  Participants with cancer recurrence or metastasis

          -  Participants with weight change more than 5kg in the previous 3 months

          -  Participants with secondary causes of obesity, such as hypothyroidism

          -  Participants with hepatic disease (aspartate aminotransferase (AST)/alanine
             aminotransferase (ALT) &gt;3 x institutional upper limit of normal) or renal disease
             (serum creatinine &gt;2.0 mg/dL)

          -  Participants with serious psychiatric illness, including bipolar disorder,
             schizophrenia, or other psychosis, bulimia, anorexia nervosa, or suicidal ideation

          -  Participants who are taking weight loss medications

          -  Participants who are receiving systemic corticosteroid therapy

          -  Participants with alcohol abuse or dependence

          -  Any condition which in the opinion of the investigator makes the subject unsuitable
             for inclusion in this study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 25, 2019</study_first_submitted>
  <study_first_submitted_qc>August 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2019</study_first_posted>
  <last_update_submitted>August 2, 2019</last_update_submitted>
  <last_update_submitted_qc>August 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gangnam Severance Hospital</investigator_affiliation>
    <investigator_full_name>Ji-Won Lee</investigator_full_name>
    <investigator_title>Associate Professor, Department of Family Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

